FDA approves pritelivir for treatment-resistant herpes lesions in immunocompromised adults
- On 9 October 2026 the FDA approved Hovilpri (pritelivir) tablets for herpes simplex lesions in immunocompromised adults.
- Pritelivir is for skin and mucosal lesions that did not respond to acyclovir, valacyclovir or famciclovir.
- In the PRIOH-1 trial, all lesions healed by day 28 in 63% of pritelivir patients versus 34% on comparator drugs.
- Headache was the most common side effect of pritelivir.
The US Food and Drug Administration approved Hovilpri (pritelivir) tablets on 9 October 2026 for skin and mucosal lesions caused by herpes simplex virus in immunocompromised adults whose lesions did not respond to acyclovir, valacyclovir or famciclovir. Aicuris developed the drug, Asahi Kasei Therapeutics markets it in the US, and the application had priority review.
A different mechanism
Pritelivir is a helicase-primase inhibitor. Unlike standard nucleoside analogues, it does not need a viral enzyme to be activated. According to the company it is active against HSV-1 and HSV-2, including strains resistant to standard drugs.
Trial results
Approval rests on part C of the phase 3 PRIOH-1 trial, an open-label study of 101 immunocompromised adults that compared pritelivir with the investigator's choice of foscarnet, cidofovir or imiquimod. All lesions healed by day 28 in 63% of pritelivir patients versus 34% of comparators, and lesion response through day 42 reached 82% versus 42%.
Safety and interactions
Adverse reactions occurred in 22% of pritelivir patients versus 54% on comparators, and headache was the most common (6%). Acid-reducing drugs can lower pritelivir levels. The trial was small and open-label, so patients and doctors knew which treatment was given.
Sources: FDA — Novel Drug Approvals 2026, Contagion Live, Contemporary OB/GYN
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is Hovilpri (pritelivir)?
Hovilpri (pritelivir) is an oral helicase-primase inhibitor that the FDA approved on 9 October 2026 for treatment-resistant herpes simplex lesions in immunocompromised adults.
When is pritelivir used?
Pritelivir is used when herpes skin or mucosal lesions in immunocompromised adults have not responded to acyclovir, valacyclovir or famciclovir.
How well did pritelivir work in PRIOH-1?
In PRIOH-1, all lesions healed by day 28 in 63% of pritelivir patients versus 34% of patients on the investigator's chosen comparator.
What are the common side effects of pritelivir?
Headache was the most common side effect of pritelivir, reported in 6% of patients, and overall side effects were less frequent than with comparator drugs.
Does pritelivir interact with other drugs?
Yes. Acid-reducing medicines can lower pritelivir absorption and effectiveness, so some should be avoided or limited in dose.



